Trials / Active Not Recruiting
Active Not RecruitingNCT06625177
A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo. A secondary objective is to further evaluate the safety of TEV-53408. The planned study period per participant is 84 weeks including a screening period (up to 4 weeks), a 24-week open-label treatment period, a 16-week washout period, and a 40-week follow-up period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TEV-53408 | TEV-53408 injection administered subcutaneously |
Timeline
- Start date
- 2024-11-11
- Primary completion
- 2026-05-09
- Completion
- 2027-06-05
- First posted
- 2024-10-03
- Last updated
- 2026-02-05
Locations
13 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06625177. Inclusion in this directory is not an endorsement.